The West Metro-Minneapolis Community Clinical Oncology Program (WMMCCOP) represents a consortium of seven hospitals which, through its operational NCI-funded CHOP program, has already developed a common approach to the management of cancer patients and has an established mechanism for the integration of protocols and patient management guidelines. The consortium has a community-wide, computerized data management system (TUMORS) capable of prospective data collection. Together, the seven hospitals see an average of 3,600 new, analytic cancer patients per year. The twenty core investigators have also worked extensively together on cancer program development. Several investigators have experience as ECOG cancer control affiliates through the University of Minnesota (UM). The WMMCCOP intends to: develop a close working relationship with UM-ECOG on the design, use and quality control of protocols; establish a data management plan with a high degree of quality control, feedback to physicians and capability of providing data for NCI's overall evaluation and diffusion hypothesis; and establish a mechanism to control the use of pharmaceutical agents through its existing, experienced pharmacy. During 1981, WMMCCOP investigators entered 115 patients on NCI approved protocols. Forty-seven patients were entered on protocol from April to June, 1982. During the first year of WMMCCOP operation, investigators intend to enter 245 patients onto ECOG protocols.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035267-05
Application #
3557667
Study Section
(SRC)
Project Start
1983-09-01
Project End
1990-05-31
Budget Start
1988-06-01
Budget End
1989-05-31
Support Year
5
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Park Nicollet Institute
Department
Type
DUNS #
City
Minneapolis
State
MN
Country
United States
Zip Code
55416
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Schneider, Bryan P; O'Neill, Anne; Shen, Fei et al. (2015) Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 113:1651-7

Showing the most recent 10 out of 76 publications